When T cells from a bone marrow donor begin to attack the host within 3 months after
hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease …

Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …

Prior studies suggest increased cytomegalovirus (CMV) infection after haploidentical donor
transplantation with posttransplant cyclophosphamide (HaploCy). The role of allograft …

Posttransplantation cyclophosphamide (PTCy) recently has had a marked impact on human
allogeneic hematopoietic cell transplantation (HCT). Yet our understanding of how PTCy …

Allogeneic blood or bone-marrow transplantation (alloBMT) is a potentially curative
treatment for a variety of haematological malignancies and nonmalignant diseases …

Graft-versus-host disease (GVHD) is the most important complication of allogeneic
hematopoietic stem cell transplantation (alloHSCT). We performed a prospective …

The key immunologic signatures associated with clinical outcomes after posttransplant
cyclophosphamide (PTCy)-based HLA-haploidentical (haplo) and HLA-matched bone …

Autoimmune diseases are characterized by an imbalance between regulatory T cells and
effector T-cell subsets, such as Th1 and Th17 cells. Studies have confirmed that natural …

Post-transplantation cyclophosphamide (PTCy) has been highly successful at preventing
severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic …

Regulatory T cells (Treg) are conventionally viewed as suppressors of endogenous and
therapy-induced antitumor immunity; however, their role in modulating responses to immune …